Literature DB >> 12934971

Noncholinergic treatment options for Alzheimer's disease.

Mary Sano1.   

Abstract

Approved treatments for Alzheimer's disease have focused primarily on cholinergic enhancement. New attention, however, is being turned toward preventative treatments such as vitamin E, estrogen, and lipid-lowering agents. Preventative treatments focus on intervening prior to the onset of disease. These treatments are designed to modify the amyloid load. These new approaches require designs that select nonimpaired or minimally impaired populations, using new outcomes with prolonged assessment. The cost of these studies is high, but the potential benefit of delay or prevention of disease is the valuable goal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12934971

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Amyloid, tau, and cell death in Alzheimer's disease.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-08-26

Review 2.  Adiposity and Alzheimer's disease.

Authors:  José A Luchsinger; Deborah R Gustafson
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2009-01       Impact factor: 4.294

Review 3.  Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.

Authors:  José Alejandro Luchsinger
Journal:  Eur J Pharmacol       Date:  2008-03-04       Impact factor: 4.432

Review 4.  Adiposity, type 2 diabetes, and Alzheimer's disease.

Authors:  José A Luchsinger; Deborah R Gustafson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

5.  Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.

Authors:  Huajie Li; Jian Wu; Linfeng Zhu; Luolin Sha; Song Yang; Jiang Wei; Lei Ji; Xiaochun Tang; Keshi Mao; Liping Cao; Ning Wei; Wei Xie; Zhilong Yang
Journal:  Biosci Rep       Date:  2018-01-10       Impact factor: 3.840

Review 6.  Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems.

Authors:  Randi J Hagerman; Deborah A Hall; Sarah Coffey; Maureen Leehey; James Bourgeois; John Gould; Lin Zhang; Andreea Seritan; Elizabeth Berry-Kravis; John Olichney; Joshua W Miller; Amy L Fong; Randall Carpenter; Cathy Bodine; Louise W Gane; Edgar Rainin; Hillary Hagerman; Paul J Hagerman
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.